Drugs / NRT6003 Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06900543 | Apr 2025 → Oct 2027 expected | hepatocellular carcinoma | Chengdu New Radiomedicine Technology Co. LTD. | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NRT6003 Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06900543 ↗ |